List of Contents

Cell Banking Outsourcing Market Size, Share, and Trends 2024 to 2034

The global cell banking outsourcing market size accounted for USD 14.38 billion in 2024, grew to USD 16.07 billion in 2025 and is expected to be worth around USD 43.59 billion by 2034, registering a solid CAGR of 11.72% between 2024 and 2034. The North America cell banking outsourcing market size is calculated at USD 5.90 billion in 2024 and is estimated to grow at a fastest CAGR of 11.86% during the forecast period.

  • Last Updated : October 2024
  • Report Code : 5153
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cell Banking Outsourcing Market 

5.1. COVID-19 Landscape: Cell Banking Outsourcing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cell Banking Outsourcing Market, By Type

8.1. Cell Banking Outsourcing Market, by Type, 2024-2034

8.1.1 Master Cell Banking

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Working Cell Banking

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Viral Cell Banking

8.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Cell Banking Outsourcing Market, By Cell Type

9.1. Cell Banking Outsourcing Market, by Cell Type, 2024-2034

9.1.1. Stem Cell

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Non-Stem Cell

9.1.2.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Cell Banking Outsourcing Market, By Phase

10.1. Cell Banking Outsourcing Market, by Phase, 2024-2034

10.1.1. Bank Storage

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Bank Characterization & Testing

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Bank Preparation

10.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Cell Banking Outsourcing Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2021-2034)

11.1.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.1.3. Market Revenue and Forecast, by Phase (2021-2034)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2021-2034)

11.1.4.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.1.4.3. Market Revenue and Forecast, by Phase (2021-2034)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2021-2034)

11.1.5.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.1.5.3. Market Revenue and Forecast, by Phase (2021-2034)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2021-2034)

11.2.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.2.3. Market Revenue and Forecast, by Phase (2021-2034)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2021-2034)

11.2.4.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.2.4.3. Market Revenue and Forecast, by Phase (2021-2034)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2021-2034)

11.2.5.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.2.5.3. Market Revenue and Forecast, by Phase (2021-2034)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2021-2034)

11.2.6.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.2.6.3. Market Revenue and Forecast, by Phase (2021-2034)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2021-2034)

11.2.7.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.2.7.3. Market Revenue and Forecast, by Phase (2021-2034)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2021-2034)

11.3.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.3.3. Market Revenue and Forecast, by Phase (2021-2034)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2021-2034)

11.3.4.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.3.4.3. Market Revenue and Forecast, by Phase (2021-2034)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2021-2034)

11.3.5.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.3.5.3. Market Revenue and Forecast, by Phase (2021-2034)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2021-2034)

11.3.6.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.3.6.3. Market Revenue and Forecast, by Phase (2021-2034)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2021-2034)

11.3.7.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.3.7.3. Market Revenue and Forecast, by Phase (2021-2034)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2021-2034)

11.4.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.4.3. Market Revenue and Forecast, by Phase (2021-2034)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2021-2034)

11.4.4.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.4.4.3. Market Revenue and Forecast, by Phase (2021-2034)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2021-2034)

11.4.5.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.4.5.3. Market Revenue and Forecast, by Phase (2021-2034)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2021-2034)

11.4.6.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.4.6.3. Market Revenue and Forecast, by Phase (2021-2034)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2021-2034)

11.4.7.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.4.7.3. Market Revenue and Forecast, by Phase (2021-2034)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2021-2034)

11.5.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.5.3. Market Revenue and Forecast, by Phase (2021-2034)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2021-2034)

11.5.4.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.5.4.3. Market Revenue and Forecast, by Phase (2021-2034)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2021-2034)

11.5.5.2. Market Revenue and Forecast, by Cell Type (2021-2034)

11.5.5.3. Market Revenue and Forecast, by Phase (2021-2034)

Chapter 12. Company Profiles

12.1. Bio Outsource (Sartorious)

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. BSL Bioservice

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Cryo-Cell International, Inc

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Charles River Laboratories

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. LifeCell

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. GBI

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Lonza

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. SGS Société Générale de Surveillance SA

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Perfectus Biomed Limited

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client